Case Of Osteosarcoma Research Articles

71TiP P16 protein expression as a predictive biomarker for response to neoadjuvant chemotherapy in osteosarcoma

Osteosarcoma is the most common primary malignancy of bone in children and young adults. Necrotic response in the tumor specimen after preoperative chemotherapy is a reproducible and reliable prognostic marker for survival in patients with OS. Pathologic tumor necrosis 90% or greater in the surgical specimen has been correlated with a 5-year survival of 75% to 90%. Although several molecular markers, including P-glycoprotein, Ki-67, p53, ezrin and HER2 have been associated with OS, a clear consensus has not emerged regarding the prognostic and predictive significance. The downregulation of p16 INK4A proteins is found in around 60% of high-grade osteosarcomas and plays an important role in growth of osteosarcoma cells by deregulation of both the pRb and p53 cell growth control pathways. Based on previously published studies, p16 protein negative expression on IHC is a predictive biomarker to poor pathologic response to neoadjuvant chemotherapy and is associated with a worse prognosis. p16 expression is correlated to the tumor biology and is not influenced by chemotherapy treatment. Thus, given the paucity of Indian data and lack of prospective studies, we aimed to investigate the role of P16 protein expression as a predictive biomarker in osteosarcoma. Aim: To investigate the relationship of p16 expression in pretreatment osteosarcoma tumors to pathologic necrotic response after neoadjuvant chemotherapy in a prospective pilot study. Inclusion criteria: Histologically proven cases of newly diagnosed osteosarcoma planned for neoadjuvant chemotherapy. Exclusion criteria: 1. Metastatic and relapsed osteosarcoma; 2. Upfront operated cases of osteosarcoma; 3. Prior therapy. Study procedure: Immuno-histochemistry for p16 will be conducted in core biopsy samples upfront before starting neoadjuvant chemotherapy in newly diagnosed case of osteosarcoma tumor cell necrosis rate will be calculated after neoadjuvant chemotherapy on surgical specimen. The grade of tumour cell necrosis rate will be classified using the Huvos necrosis grading system P16 correlation with good response to chemotherapy in terms of tumour necrosis will be evaluated. The author.

Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group.

BackgroundThe outcomes of unplanned surgery for bone sarcomas have not been frequently discussed. However, it is important to recognize patterns, treatment, and clinical outcomes of unplanned surgeries for patients with bone sarcomas. This multicenter study aimed to characterize the clinical outcomes of patients with bone sarcomas who underwent unplanned surgeries.Patients and MethodsData of 43 patients with bone sarcomas who underwent unplanned surgery between 2006 and 2017 were obtained from 23 hospitals in Japan. These included 18 cases of osteosarcoma, 9 of Ewing sarcoma, 8 of chondrosarcoma, and 6 of undifferentiated pleomorphic sarcoma. The study included 28 men and 15 women, with a mean age of 46 years. The mean follow-up duration was 59 months.ResultsThe main primary tumor sites were the femur (n = 19), spine (n = 6), pelvis (n = 5), tibia (n = 3), and humerus (n = 3). The primary diagnoses were benign bone tumor (n = 24), trauma (n = 7), bone metastasis (n = 5), osteomyelitis (n = 4), degeneration (n=2), and unknown (n = 1). As unplanned surgeries, curettage, with or without bone graft, was performed in 26 patients; internal fixation was performed in 7; spinal surgery in 5; arthroplasty in 4; and arthroscopy in one. Thirty-eight patients received additional standard treatments. Thirty-four of these patients underwent surgical tumor resections, including amputation (n = 10), and the remaining 4 received radiotherapy or carbon ion radiotherapy as additional standard treatments. The 5-year disease-specific survival (DSS) rates in patients with osteosarcoma, Ewing sarcoma, and chondrosarcoma were 65.5%, 58.3%, and 72.9%, respectively. Twelve (27.9%) patients developed local recurrences (LR); among the total 43 patients studied, the 5-year DSS rates were significantly worse for those who developed LR compared to those who did not (p = 0.03). The 5-year DSS rates in patients with and without LR were 44% and 73.8%, respectively.ConclusionWe recommend that patients who have undergone unplanned surgery be administered standard treatment, including the option of amputation because herein, LR was shown to be a risk factor for decreased DSS.

Maxillary osteosarcoma: a case report and review of maxillary sinus space-occupying lesions

Osteosarcoma is a relatively rare lesion in the maxillary bone. The proximity of the lesion to the maxillary sinus provides a null space with the minimum resistance to progress prior to manifest clinically, which makes the early diagnosis more critical. We report a case of maxillary osteosarcoma in a 21-year old male patient who was presented with the chief complaint of the pain and swelling on the left side of palate since 2 months earlier. A cone-beam computed tomography of the maxilla revealed a diffuse hyper-intense entity at the left side of the maxilla. Totally-occupied maxillary sinus space, asymmetric periodontal ligament widening of the involved teeth and spiculated and sunray periosteal reaction were recognized. The diagnosis of osteosarcoma was established and confirmed by histopathology. This article reviews the sinus-occupying lesion in the following and describes the lesions originate within the maxillary sinus or arise from the adjacent odontogenic components. Keywords Case report; Maxillary sinus; Osteosarcoma.

Large-extension osteosarcoma with involvement of multiple maxillofacial structures: a rare case report

Background: Osteosarcoma is a malignant neoplasm that occurs most often in long bones, with the head and neck region being rarely affected, accounting for less than 1% of all cancers in this region. Objective: To report a rare case of a large-extension osteosarcoma with emphasis on its clinical and diagnostic aspects. Case presentation: A 43-year-old woman presenting an intraoral exophytic lesion with involvement of other maxillofacial structures, such as nostril, zygoma and orbit. Despite the initial clinical diagnosis of actinomycosis, an incisional biopsy confirmed the histopathological diagnosis of osteosarcoma, showing a wide morphological variety. Conclusion: This case highlights the importance of clinical and histopathological findings for the correct diagnosis of osteosarcoma. Moreover, it shows that, although surgical resection is the primary treatment for this neoplasia, depending on the extent of the tumor and its proximity to vital anatomical structures, the most appropriate conduct is not always feasible.

Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.

PurposeDuring preclinical testing, teriparatide caused a dose‐dependent increase in the incidence of osteosarcoma in rats. This study compared the incidence rate of osteosarcoma among patients aged ≥65 years treated with teriparatide vs a matched‐comparator cohort.MethodsThis population‐based comparative‐cohort study matched exposure details for each teriparatide user, identified via Medicare Part D prescription claims, and up to four comparators based on age, sex, zip code, date of claim for filled prescription, and number of unique therapeutic classes dispensed. Outcomes were identified via linkage with participating cancer registries. All US state cancer registries were invited to participate.ResultsOverall, 153 316 patients in the teriparatide cohort and 613 247 in the comparator cohort were linked to 811 osteosarcoma cases from 26 participating state cancer registries (68% of US patients aged ≥65 years diagnosed 2007‐2014). Analysis on a subset of cohorts revealed they were balanced for known osteosarcoma risk factors and Charlson comorbidity index. Mean duration of teriparatide treatment was 10 months. No osteosarcoma cases were observed in the teriparatide cohort; the incidence rate in the comparator cohort was consistent with the background incidence rate among adults aged ≥65 years. The incidence rate ratio was 0.0 (95% confidence interval, 0.0‐3.2).ConclusionsFor US patients aged ≥65 years, incidence of osteosarcoma among those treated with teriparatide ranges from 0 to 3.2 times the incidence of osteosarcoma in those treated with other medications. Given low incidence of osteosarcoma, this range of effect is inconsistent with a large absolute increase in osteosarcoma risk.

CHONDROBLASTIC OSTEOSARCOMA IN THE MANDIBLE: A CASE REPORT

Osteosarcoma of the jaws is uncommon and mainly occurs as a fast-growing painful swelling in the posterior mandible. The knowledge of clinicopathologic aspects of osteosarcoma is essential for early diagnosis and adequate treatment. The aim of this study is to report a clinical case of chondroblastic osteosarcoma in the posterior left mandible in a 53-year-old male patient with complaint of paresthesia in the left lower lip and a fast-growing swelling in the gingival mucosa. Radiographically, the classical sunray appearance can be observed. Microscopically, we identified atypical polygonal cells with large and hyperchromatic nuclei associated with osteoid material and chondroblastic differentiation. The diagnosis of chondroblastic osteosarcoma was made. The patient was referred to an oncologist for treatment with surgery and chemotherapy.

Definitive surgery of primary lesion should be prioritized over preoperative chemotherapy to treat high-grade osteosarcoma in patients aged 41\u201365\xa0years

BackgroundRecently, the number of osteosarcomas in middle-aged and older patients has demonstrated an increasing trend; moreover, their results are comparatively worse than those of young patients. In Europe and the USA, the prognosis for osteosarcoma in middle-aged and older patients has improved with adjuvant chemotherapy. In Japan, however, the prognosis has remained poor.Materials and MethodsWe retrospectively analyzed the outcomes of osteosarcoma, especially in regards to preoperative chemotherapy, from January 1980 to July 2014. A total of 29 patients with high-grade osteosarcoma between the age of 40 and 65 years were included. We included patients without distant metastasis and with primary lesions that were deemed resectable. The mean age was 52.8 years (range 41–65 years), and the mean follow-up period was 103.2 months (range 5–314 months).ResultsAdjuvant chemotherapy was administered to 27 of 29 patients (93%), and 8 of 15 cases (53%) were able to undergo preoperative chemotherapy as planned, including CDDP. A major complication of chemotherapy was acute kidney injury due to CDDP (26%). The 5-year OS and 5-year EFS were 64.9% and 57.1%, respectively. After 2006, a policy to prioritize the resection of the primary lesion was implemented, and if the primary lesion was deemed resectable, preoperative chemotherapy was either not administered or administered for only a short duration. The 5-year OS after 2006 improved to 78.8%.ConclusionsThis study shows that administration of high-dose intensity preoperative chemotherapy was difficult in middle-aged and older patients due to their high rate of acute kidney injury by CDDP. For cases of osteosarcoma in middle-aged and older patients, if the primary lesion is resectable, preoperative chemotherapy should be minimized to prioritize the resection of the primary lesion. It was considered that, with appropriate measures to prevent complications, adjuvant chemotherapy may lead to improved prognosis.Level of evidenceV.

Nomograms for predicting overall survival and cancer-specific survival of chondroblastic osteosarcoma patients.

The establishment of precise and personalized prediction systems for chondroblastic osteosarcoma patients is important for guiding the treatment. The univariate logrank test and multivariate Cox regression analysis were performed to identify independent prognostic factors for overall survival (OS) and cancer-specific survival (CSS). Nomograms were constructed to estimate the OS and CSS based on these factors. Internal and external validation was performed. The predictive power of the nomograms was determined by C-index and calibration plots. A total of 401 chondroblastic osteosarcoma cases were identified. Univariate and multivariate analysis revealed that age at diagnosis, histological grade, tumor size, Surveillance, Epidemiology, and End Results stage, and surgical resection were independent prognostic factors for OS and CSS. The five factors were incorporated to construct the nomograms for estimating the 3- and 5-year OS and CSS. The C-index values for the internal validation of the OS and CSS nomogram were 0.732 and 0.746, respectively, and for the external validation were 0.780 and 0.808, respectively. The calibration curves revealed that the predicted OS and CSS could well match the actual survival rate. The nomograms for predicting 3- and 5-year OS and CSS were constructed and were proved to be accurate and reliable by the internal and external validation.

Osteosarcoma of the Jaws: A Literature Review.

Osteosarcoma of the jaws (OSJ) is a relatively rare disease, accounting for between 2% and 10% of all cases of osteosarcoma. It is morphologically and radiologically identical to the trunk and extremity variant, but distinct in several crucial aspects. The lesion is characterized by sarcomatous cells which produce a variable amount of osteoid bone. It arises centrally within the bone and can be subdivided into osteoblastic, chondroblastic and fibroblastic subtype, depending on the predominant cell type. Radiographically, these tumors display a spectrum of bone changes from well-demarcated borders to lytic bone destruction with indefinite margins and variable cortical bone erosion or, in some cases, images of sclerotic bone. Therapeutic options for OSJ include surgery, chemotherapy and radiotherapy, which are employed according to age of the patient, histological classification and localization of the tumor. Today, there is no general consensus in the treatment guidelines for the OSJ though surgery represents the key to the treatment. The main prognostic factor deeply influencing the patient's prognosis remains the complete tumor resection with negative surgical margins. The aim of the present review is to describe state of the art regarding diagnostic and surgical treatment aspects of the primary osteosarcoma of the jaws.

First case of osteosarcoma in a dinosaur: a multimodal diagnosis

First case of osteosarcoma in a dinosaur: a multimodal diagnosis

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

The prognostic factors for survival among patients with secondary osteosarcoma remain unclear. The aim of this study was to develop a practical nomogram for predicting cancer-specific survival (CSS) in patients with osteosarcoma as a secondary malignancy. The surveillance, epidemiology, and end results database was used for the identification of osteosarcoma cases. The total sample comprised 5860 cases of primary osteosarcoma and 268 cases of secondary osteosarcoma during the period from 1973 to 2015. The CSS and overall survival (OS) of primary and secondary osteosarcomas were analyzed. The predictors of CSS for secondary osteosarcoma were identified and integrated to build a nomogram. Validation of the nomogram was performed using concordance index (C-index) and calibration plots. The results indicated that patients with secondary osteosarcoma had poorer CSS and OS than patients with primary osteosarcoma. The nomogram model exhibited high discriminative accuracy in the training cohort (C-index = 0.826), which was confirmed in the internal validation cohort (C-index = 0.791). In addition, the calibration plots confirmed good concordance for prediction of CSS at 3, 5, and 10 years. In conclusion, we developed a practical nomogram that provided individual predictions of CSS for patients with secondary osteosarcoma. This nomogram may help clinicians with prognostic evaluations and with the development of individualized therapies for this aggressive disease.

Abstract B26: Prometastatic effect of ICG-001, a β-catenin/CBP dependent transcription inhibitor, in osteosarcoma

Abstract Osteosarcoma is the most common malignant bone tumor in the pediatric population, representing around 4 cases per million people per year in the world. Patient survival is closely related to the response of tumor cells to chemotherapy, reaching 70% at 5 years for patients with localized disease, but only 25% for high-risk patients with relapsed or metastatic disease. In 20% of cases, patients have detectable metastases at diagnosis, preferentially in the lungs, which is a sign of poor prognosis. However, it is estimated that around 80% of patients have pulmonary micrometastases, sometimes undetectable at diagnosis by imaging techniques. This makes metastatic dissemination a significant issue in the management of osteosarcoma. In addition, the survival rate has not evolved since the past decades and there is no current efficient therapy for these patients. Therefore, it is necessary to develop new therapeutic strategies. In this context, a dysregulation of the canonical Wnt signaling pathway (Wnt/β-catenin) has been reported in many osteosarcoma cases, but its implication in the development of primary and metastatic osteosarcoma is still controversial. An increase in β-catenin expression has been described in human osteosarcoma tissues compared to normal bones. Thus, we evaluated the antitumor potential of ICG-001, a small molecule that specifically binds to the transcriptional co-activator CREB-Binding Protein (CBP), disrupting its interaction with β-catenin and thus suppressing the Wnt/β-catenin target gene expression. First, we demonstrated that ICG-001 inhibits β-catenin/CBP-dependent transcription as evaluated by TCF-LEF reporter assay and RT-qPCR on β-catenin target genes in three human osteosarcoma cell lines, KHOS, MG63, and SJSA1. Moreover, ICG-001 decreases proliferation of osteosarcoma cells in a dose- and time-dependent manner, associated with a cell cycle blockade in G0/G1 phase after 24h of treatment, but without any effect on cell death. However, surprisingly, ICG-001 promotes KHOS, MG63, and SJSA1 cell migration in vitro and the development of pulmonary metastases in a murine xenograft model of osteosarcoma induced by injection of KHOS cells in a paratibial site. This study therefore raises new questions about the role of the Wnt/β-catenin pathway in the metastatic development of osteosarcoma. Thus, it is necessary to identify the different signatures of the signaling pathways potentially activated after disruption of the β-catenin and CBP interaction in osteosarcoma cells and responsible for the prometastatic effect of this drug. Citation Format: Geoffroy Danieau, Sarah Morice, Sarah Renault, Kevin Biteau, Régis Brion, Jérôme Amiaud, Frédéric Lezot, Franck Verrecchia, Françoise Rédini, Bénédicte Brounais-Le Royer. Prometastatic effect of ICG-001, a β-catenin/CBP dependent transcription inhibitor, in osteosarcoma [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr B26.

Craniofacial Osteosarcoma-Pilot Study on the Expression of Osteobiologic Characteristics and Hypothesis on Metastasis.

Background: Craniofacial osteosarcomas (COS) and extracranial osteosarcomas (EOS) show distinct clinical differences. COS show a remarkably lower incidence of metastases and a better survival. However, in contrast to EOS, they show a poor response to neoadjuvant chemotherapy. Tumor-associated macrophages and their polarization as well as developmental biological signaling pathways are possible candidates for explaining the clinical differences between COS and EOS. The aim of the study was to analyze differential expression of macrophage markers and important regulators of these pathways.Methods: Twenty osteosarcoma cases (10 COS and 10 EOS) were immunohistochemically stained to assess CD68, CD11c, CD163, MRC1, Gli1, and Gli2 expression. Statistical differences between COS and EOS were tested using the Mann–Whitney U test. Additionally, the paper describes an example of multidisciplinary treatment of a patient suffering from COS and discusses the surgical challenges in treatment and rehabilitation of COS.Results: COS showed a significantly (p < 0.05) increased infiltration of CD11c-positive M1 macrophages and a shift toward M1 polarization compared to EOS. Additionally, COS revealed a significantly (p < 0.05) lower Gli1 expression than EOS.Conclusion: The reduced Gli1 expression in COS can be interpreted as reduced activation of the Hedgehog (Hh) signaling pathway. The increased M1 polarization and reduced Hh activation in COS could explain the low incidence of metastases in these osteosarcomas.

A case of low-grade central osteosarcoma of the mandible

Low-grade central osteosarcoma, a rare subtype of osteosarcoma, is less aggressive than conventional osteosarcoma. We report ac case of low-grade central osteosarcoma of the mandible. A 52-year-old woman presented to our department for treatment of a swelling in the right side of the mandible. Computed tomography revealed ground glass radiopaque lesions associated with an expansive growth pattern in the mandibular bone. Because a suspicion of low-grade central osteosarcoma was diagnosed In the biopsy sample provided from the previous hospital, the lesion was surgically resected. Histopathologically, the tumor consisted of a dense proliferation of spindle cells with mild atypia. At the periphery of the lesion, the normal cortical bone was invaded by tumor nests. Low-grade central osteosarcoma was diagnosed in the surgical specimen. Tumor recurrence has not been observed for more than 6 years after surgery. Low-grade central osteosarcoma is hard to differentiate from osteogenic benign neoplasm or bone malformation. Therefore, when radiographic findings reveal an expansive ground glass appearance, a bone biopsy including the normal cortical bone and the central part of the lesion is essential.

Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.

This study is an evaluation of the overall survival rate and factors affecting survival in patients with osteosarcoma, chondrosarcoma, or Ewing's sarcoma. This study aimed to determine the effect of factors related to the preoperative period, patient, tumor, treatment, and postoperative period on survival. A total of 114 patients (64 male and 50 female) with osteosarcoma, chondrosarcoma, or Ewing's sarcoma treated between 2005 and 2013 were included in this study. All the patients received standard treatment and were followed up regularly. In all, 44 cases of (conventional and telangiectatic) osteosarcoma, 30 cases of Ewing's sarcoma, and 40 cases of high-grade chondrosarcoma were identified using the Bone and Soft Tissue Tumor Registry. Gender, age, tumor size and localization, pathological fractures, histopathological type, grade, surgical treatment, adjuvant treatments, relapse of the disease, and postoperative complication data were obtained from follow-up forms. The learning curve of institutional expertise was also evaluated. The patient survival rate was calculated using the Kaplan-Meier method, and log-rank statistical methods were used to compare survival rates. The mean length of survival of the patients was 72 months. There was a 56% 5-year survival rate, and the event-free survival rate was 53%. The survival of patients with Ewing's sarcoma whose prodromal period was less than 12 weeks was significantly higher than that of the other groups (p=0.031). The survival of patients with tumor size greater than 150 cc, with local recurrence and distant metastases was low for all groups. Survival rates were significantly lower in osteosarcoma and Ewing's sarcoma patients with stage III tumor or metastasis at diagnosis. The survival of patients with osteosarcoma diagnosed between 2010 and 2013 was significantly higher than that of the earlier group (p=0.02). Decreasing the prodromal period (early diagnosis) can improve survival by preventing the local and systemic spread of the tumor. Increase in the surgical experience is likely to have a positive effect on survival rates, especially for patients with osteosarcoma. The relapse of the disease is a poor prognostic factor for survival despite aggressive surgery and adjuvant therapies. Level IV, Therapeutic study.

Re-challenge with High Dose Methotrexate vs. Reduced Dose After Methotrexate Toxicity in Pediatric Osteosarcoma:Case Report

Introduction: Methotrexate (MTX), a classic antifolate, is one of the most widely used and well-studied anticancer agents. High-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is one of the standard therapies for osteosarcoma. High-dose methotrexate (HDMTX) can exert significant toxicity and requires complex pharmacokinetic monitoring and leucovorin rescue. The side effect profile of MTX varies markedly according to the dose. Regimens containing MTX are classified as high, intermediate, or low-dose. High-dose methotrexate (HD-MTX; 12 g/m2) is a part of the golden standard therapy for pediatric osteosarcoma (OS). Risk factors associated with MTX toxicity in children with OS are not well defined. Case Presentation: We report here a case of pediatric osteosarcoma with nephrotoxicity associated with delayed MTX excretion who was successfully managed using supportive measures that encouraged us to re-challenge with a full dose of MTX then we reduced the dose to 50% to attain the final critical decision about continuation or changing the regimen of treatment for the patient. Our patient developed moderate renal complications during therapy that improved with supportive care, so we challenged with more cycles of a high dose MTX, but the patient developed serious renal complications. A reduced dose of MTX with 50% was given successfully without any renal impairment. Conclusion: Methotrexate toxicity that might not occur during the initial courses of high-dose MTX is not a predictive of the tolerability of further courses and re-challenging with HDMTX is risky, but reduced dose methotrexate is a good option rather than changing the regimen, with good tolerability and rapid clearance of HDMTX. HDMTX-induced renal impairment occurs in a low percentage of patients with osteosarcoma and can be managed successfully by maximum supportive care. MTX clearance can be affected by gender and age.

Parosteal Osteosarcoma: A Benign-Looking Tumour, Amenable to a Variety of Surgical Reconstruction.

Osteosarcoma arising from cortical surface is classified into parosteal, periosteal and high-grade surface osteosarcoma. Along the spectrum, parosteal osteosarcoma occupies the well-differentiated end. It is a relatively rare disease entity, comprised only 4% of all osteosarcomas and barely reported in the literature. The objective of this study is to describe cases of parosteal osteosarcoma as well as a variety of treatment options amenable to such entity. Six cases of parosteal osteosarcoma were identified based on histopathological reports in a tertiary referral hospital in Jakarta, Indonesia between January 2001 and December 2019. The mean age was 29.8 years old; four of them (66.7%) were male. Distal end of femur was the most commonly involved bone (five cases, 83.3%). The patients were treated with wide excision followed by several different reconstruction methods: replacement with endoprosthesis, extracorporeal irradiation, knee arthrodesis, or prophylactic fixation. One of our patients presented with dedifferentiated component, and therefore was treated by limb ablation. While two cases died of pulmonary metastasis, other patients reported fair to excellent functional outcome.

Effective factors on clinical outcomes of children with osteosarcoma and Ewing bone tumors

Introduction: Malignant bone tumors account for 6% of childhood malignancies. The peak incidence rate for bone cancer is in adolescents. Geographic and race differences in incidence rate of bone tumors are important for correct diagnosis and treatment. Objectives: This study aimed to investigate the demographic features of patients with malignant bone tumors and prognostic factors. Patients and Methods: In a retrospective study, records of all patients diagnosed and treated for malignant bone tumor from March 1996 to February 2014 were investigated. Data were collected using checklists and analyzed using SPSS software. Results: The most common type of bone tumor was Ewing sarcoma (73.7%) in patients who were over 10 years old (87.5%). Primary site of disease in most cases of osteosarcoma and Ewing sarcoma was distal femur (50% and 27.3%, respectively). Most common clinical manifestation was local pain and mass (88.5%). Regarding metastasis, 72.7% of osteosarcoma patients and 32.4% of Ewing sarcoma patients had metastasis. There was not statistically relationship between survival rate and gender, age group and stage of disease at diagnosis time. One, three and five-year survival rate was lower than the previous studies. Conclusion: The incidence of Ewing sarcoma is more then osteosarcoma in West Azerbaijan. In our study there were no statistically important differences in survival rates of patients with metastasis at diagnosis time and those without metastasis.

Osteosarcoma in a Dachshund: cytological and histopathological aspects

Malignant primary bone neoplasms are characterized by high malignancy and metastatic capacity, commonly affecting dogs of large or giant breeds. The prognosis is reserved to unfavorable for the patients. This paper describes a case of osteosarcoma in the left pelvic limb of a Dachshund, diagnosed by fine-needle aspiration cytology and confirmed by histopathological evaluation. The patient underwent limb amputation and doxorubicin chemotherapy; however, the dog died. This report alerts clinicians to the occurrence of osteosarcoma in small animals and demonstrates the importance of fine-needle aspiration cytology as a tool in the diagnosis of bone neoplasms.

面部皮肤原发性骨外骨肉瘤一例

面部皮肤原发性骨外骨肉瘤一例